FDA supplemental approval: Oxycodone AND Acetaminophen (REMS)

AI Summary

The FDA approved a supplemental REMS (Risk Evaluation and Mitigation Strategy) for an oxycodone–acetaminophen combination product in two tablet strengths (325 mg acetaminophen + 7.5 mg oxycodone HCl, and 325 mg acetaminophen + 10 mg oxycodone HCl) manufactured by Watson Labs, effective 18 June 2026. This regulatory action establishes risk mitigation requirements but does not constitute a clinical efficacy or safety trial and does not imply new evidence of benefit or harm.

Plain-language summary

FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for an existing oxycodone–acetaminophen combination product; this is a regulatory action, not a clinical evidence assessment.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This is a regulatory action establishing post-market risk management requirements for an existing product; it does not report new clinical trial results, efficacy data, or safety outcomes. Clinicians should refer to the full REMS protocol and the product labeling for specific prescriber requirements and patient safeguards.

Caveats

• This record does not contain clinical trial results, efficacy data, or safety event outcomes.
• Specific REMS requirements and prescriber/patient obligations are not detailed in this record.
• No comparative data, effect sizes, or comparative safety/efficacy information provided.
• Approval of a REMS does not indicate new evidence of clinical benefit or harm; it is a regulatory classification action.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.